1. Adelaide Research & Scholarship

Search


Current filters:




Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 31-40 of 47 (Search time: 0.002 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2012Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trialBurmeister, B.; Henderson, M.; Ainslie, J.; Fisher, R.; Di Iulio, J.; Smithers, B.; Hong, A.; Shannon, K.; Scolyer, R.; Carruthers, S.; Coventry, B.; Babington, S.; Duprat, J.; Hoekstra, H.; Thompson, J.
2011Composite grafts in eyelid reconstruction: The complications and outcomesCannon, P.; Madge, S.; Kakizaki, H.; Selva-Nayagam, D.
2010Treatment of ocular surface squamous neoplasia with Mitomycin CGupta, A.; Muecke, J.
2010Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancerPeeters, M.; Price, T.; Cervantes, A.; Sobrero, A.; Ducreux, M.; Hotko, Y.; Andre, T.; Chan, E.; Lordick, F.; Punt, C.; Strickland, A.; Wilson, G.; Ciuleanu, T.; Roman, L.; Van Cutsem, E.; Tzekova, V.; Collins, S.; Oliner, K.; Rong, A.; Gansert, J.
2011Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX Trial of capecitabine alone or in combination with Bevacizumab and Mitomycin in advanced colorectal cancerPrice, T.; Hardingham, J.; Lee, C.; Weickhardt, A.; Townsend, A.; Wrin, J.; Chua, A.; Shivasami, A.; Cummins, M.; Murone, C.; Tebbutt, N.
2010Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian gastrointestinal trials group randomized phase III MAX studyTebbutt, N.; Wilson, K.; Gebski, V.; Cummins, M.; Zannino, D.; van Hazel, G.; Robinson, B.; Broad, A.; Ganju, V.; Ackland, S.; Forgeson, G.; Cunningham, D.; Saunders, M.; Stockler, M.; Chua, Y.; Zalcberg, J.; Simes, R.; Price, T.
2012Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: Preclinical evaluation and results of the Phase II DUX Study in chemotherapy-refractory, advanced colorectal cancerWeickhardt, A.; Price, T.; Chong, G.; Gebski, V.; Pavlakis, N.; Johns, T.; Azad, A.; Skrinos, E.; Fluck, K.; Dobrovic, A.; Salemi, R.; Scott, A.; Mariadason, J.; Tebbutt, N.
2010CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: Expanded polymorphism coverage improves risk stratificationSchroth, W.; Hamann, U.; Fasching, P.; Dauser, S.; Winter, S.; Eichelbaum, M.; Schwab, M.; Brauch, H.
2011Phase 2 trial of romidepsin in patients with peripheral T-cell lymphomaPiekarz, R.; Frye, R.; Prince, H.; Kirschbaum, M.; Zain, J.; Allen, S.; Jaffe, E.; Ling, A.; Turner, M.; Peer, C.; Figg, W.; Steinberg, S.; Smith, S.; Joske, D.; Lewis, I.; Hutchins, L.; Craig, M.; Fojo, A.; Wright, J.; Bates, S.
2013The outcomes of patients with ESRD and ANCA-associated vasculitis in Australia and New ZealandTang, W.; Bose, B.; McDonald, S.; Hawley, C.; Badve, S.; Boudville, N.; Brown, F.; Clayton, P.; Campbell, S.; Peh, C.; Johnson, D.

Discover